Evaluation of Plasma Interleukin-6 in Melanoma Patients as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker

Treatment of advanced melanoma has been revolutionized by targeted therapy (TT) and immune checkpoint blockade (ICB), but not all patients respond; identification of predictive biomarkers remains a critical need. Our prior investigations demonstrated the circulating level of C-reactive protein (CRP) as an independent melanoma prognostic biomarker (Fang et al., 2016, Fang et al., 2017, Fang et al., 2015). Interleukin-6 (IL-6) is upstream of CRP, induces hepatocyte release of CRP, and is a pleiotropic inflammatory cytokine involved in progression of melanoma (Hoejberg et al., 2012).

Source: Journal of Investigative Dermatology - December 21, 2021 Category: Dermatology Authors: Yuling Wang, Vijaya Ramachandran, Dawen Sui, Kejing Xu, Lauren E. Haydu, Shenying Fang, Jennifer L. McQuade, Sarah B. Fisher, Anthony Lucci, Emily Z. Keung, Jennifer Wargo, Jeffrey E. Gershenwald, Merrick I. Ross, Jeffrey E. Lee Tags: Letters to the Editor Source Type: research